Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 501–600 of 1,002
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3003 · Cited by 44
Dupilumab-Induced Follicular Conjunctivitis
Shen, E., Xie, K., Jwo, K., Smith, J. E., & Mosaed, S. (2018) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1533567 · Cited by 44
Kato, A., Kamata, M., Ito, M., Uchida, H., Nagata, M., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T. L., Ishikawa, T., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15464 · Cited by 46
Misery, L., Fortina, A. B., Hachem, M. E., Chernyshov, P. V., von Kobyletzki, L., Heratizadeh, A., Marcoux, D., Aoki, V., Zaniboni, M. C., Stalder, J. F., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16916 · Cited by 50
Therapeutic targeting of the IL-13 pathway in skin inflammation
Tubau, C., & Puig, L. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1858802 · Cited by 50
Napolitano, M., Maffei, M., Patruno, C., Leone, C. A., Guida, A. D., Potestio, L., Scalvenzi, M., & Fabbrocini, G. (2021) · Dermatologic Therapy · doi:10.1111/dth.15120 · Cited by 46
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Chen, Z., Thomas, R. B., Kosloski, M. P., Dubost-Brama, A., Prescilla, R. P., Bansal, A., et al. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01016-9 · Cited by 49
Self-citationKusari, A., Han, A. M., Schairer, D. O., & Eichenfield, L. F. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.07.003 · Cited by 51
Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome
Lévy, R., Béziat, V., Barbieux, C., Puel, A., Bourrat, E., Casanova, J., & Hovnanian, A. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00751-4 · Cited by 43
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
Ferreira, S., & Torres, T. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-3 · Cited by 42
Immunopathology and Immunotherapy of Inflammatory Skin Diseases
Song, A., Lee, S. E., & Kim, J. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e7 · Cited by 53
“More than half of AD patients reached EASI-75 at week 16, and 36% of patients achieved EASI-90 at week 16 with dupilumab (45).”
BackgroundCytokine-targeting biologics for allergic diseases
Lawrence, M. G., Steinke, J. W., & Borish, L. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.01.009 · Cited by 48
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis
Chang, J. W., Kliewer, K., Haller, E., Lynett, A., Doerfler, B., Katzka, D. A., Peterson, K. A., Dellon, E. S., Gonsalves, N. P., Aceves, S. S., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.006 · Cited by 46
Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
Eshtiaghi, P., & Gooderham, M. (2018) · Core evidence · doi:10.2147/ce.s133661 · Cited by 42
“001 for both PROs).(12) More recently, a third Phase III trial, CHRONOS, compared the concomitant use of dupilumab and TCS therapy with placebo and TCS treatment over 52 weeks.”
BackgroundMethodResultInfluentialDupilumab side effect in a patient with atopic dermatitis: a case report study
Al-Bader, S. S., Alharbi, A. A., Alenezi, R. F., & Alsaif, F. (2019) · Biologics · doi:10.2147/btt.s195512 · Cited by 47
“There was also a higher incidence of headache in dupilumab-treated patients than placebo-treated patients but unfortunately the mechanism is not clear and require further research.(13,14)”
BackgroundInnovación en dermatitis atópica: de la patogenia a la terapéutica
Munera‐Campos, M., & Carrascosa, J. M. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2019.11.002 · Cited by 47
Yang, X., Kambe, N., Takimoto‐Ito, R., & Kabashima, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107830 · Cited by 45
Dupilumab-associated ocular manifestations: A review of clinical presentations and management
Wu, D., Daniel, B. S., Lai, A. J. X., Wong, N. K. P., Lim, D. K.-A., Murrell, D. F., Lim, B. X. H., Mehta, J. S., & Lim, C. H. L. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.02.002 · Cited by 46
Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies
Geng, B., Bachert, C., Busse, W. W., Gevaert, P., Lee, S. E., Niederman, M. S., Chen, Z., Lu, X., Khokhar, F. A., Kapoor, U., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.12.006 · Cited by 43
Excessive Production of Hydrogen Peroxide in Mitochondria Contributes to Atopic Dermatitis
Minzaghi, D., Pavel, P., Kremslehner, C., Грубер, Ф., Oberreiter, S., Hagenbuchner, J., Frari, B. D., Blunder, S., Gruber, R. W., & Dubrac, S. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.03.1680 · Cited by 46
Simpson, E. L., Guttman‐Yassky, E., Eichenfield, L. F., Boguniewicz, M., Bieber, T. R. M., Schneider, S. K. R., Guana, A., & Silverberg, J. I. (2023) · Allergy · doi:10.1111/all.15811 · Cited by 47
Self-citationDupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Ryser, F. S., Yalamanoglu, A., Valaperti, A., Brühlmann, C., Mauthe, T., Traidl, S., Soyka, M., & Steiner, U. C. (2023) · Allergy · doi:10.1111/all.15844 · Cited by 48
Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes
Ulzii, D., Kido‐Nakahara, M., Nakahara, T., Tsuji, G., Furue, K., Hashimoto‐Hachiya, A., & Furue, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133324 · Cited by 49
“The pathogenic importance of IL-4/IL-13 signaling in AD has been recently highlighted because its blockage by dupilumab, a specific anti-IL-4 receptor α (IL-4Rα, IL4R) antibody, successfully improves skin inflammation in patients with AD [17].”
BackgroundDysfunctional adaptive immune response in adolescents and young adults with suicide behavior
Jha, M. K., Cai, L., Minhajuddin, A., Fatt, C. C., Furman, J. L., Gadad, B. S., Mason, B. L., Greer, T. L., Hughes, J. L., Xiao, G., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104487 · Cited by 41
Steck, O., Bertschi, N., Luther, F., van den Berg, J., Winkel, D. J., Holbro, A., & Schlapbach, C. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17001 · Cited by 41
Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis
Rohner, M. H., Thormann, K., Cazzaniga, S., Yousefi, S., Simon, H., Schlapbach, C., & Simon, D. (2020) · Allergy · doi:10.1111/all.14664 · Cited by 41
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment
Wong, L., & Yen, Y.-T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012390 · Cited by 48
“Dupilumab, a humanized IL-4 α receptor blocker, is approved for the treatment of AD [127].”
BackgroundZhao, Y. P., Zhang, J., Yang, B., Li, J., Ding, Y., Wu, L., Zhang, L., Wang, J., Zhu, X., Zhang, F., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002747 · Cited by 39
“Assuming that CM310 had similar efficacy results to dupilumab, [15] an enrollment of 30 participants per group would provide the trial with 80% power to detect a 36.6% difference between the CM310 high-dose group and the placebo group (51.3% vs. 14.7”
ResultInfluentialIL-4Rα Inhibitor for Atopic Disease
Chang, H. Y., & Nadeau, K. C. (2017) · Cell · doi:10.1016/j.cell.2017.06.046 · Cited by 39
Severe Atopic Dermatitis in Children
Huang, E., & Ong, P. Y. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0788-4 · Cited by 41
Recent Developments in Atopic Dermatitis
Yang, E., Sekhon, S., Sanchez, I. M., Beck, K. M., & Bhutani, T. (2018) · PEDIATRICS · doi:10.1542/peds.2018-1102 · Cited by 46
Strategies for Successful Management of Severe Atopic Dermatitis
Brar, K., Nicol, N. H., & Boguniewicz, M. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.10.021 · Cited by 44
Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses
Paller, A. S. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.08.027 · Cited by 42
“, 2016; Mansouri and Guttman-Yassky, 2015), and clinical trials have led to the recent commercial availability of the first Th2-targeting monoclonal antibody (Simpson et al., 2016).”
BackgroundManagement of dupilumab‐associated conjunctivitis in atopic dermatitis
Aszodi, N., Thurau, S., Seegräber, M., de Bruin‐Weller, M., & Wollenberg, A. (2019) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13809 · Cited by 40
Self-citationNew Insights and Treatments in Atopic Dermatitis
Saini, S., & Pansare, M. V. (2019) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2019.06.008 · Cited by 44
Implications of IL-13Rα2 in atopic skin inflammation
Furue, M., Ulzii, D., Nakahara, T., Tsuji, G., Furue, K., Hashimoto‐Hachiya, A., & Kido‐Nakahara, M. (2020) · Allergology International · doi:10.1016/j.alit.2020.01.005 · Cited by 46
Quint, T., Brunner, P. M., Sinz, C., Steiner, I., Ristl, R., Vigl, K., Kimeswenger, S., Neubauer, K., Pirkhammer, D., Zikeli, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041241 · Cited by 40
“The percentage of patients in our cohort reaching an IGA of 0/1 after 10 weeks (53%) and 24 weeks (60%) was higher than reported for the primary endpoint (16 weeks) in SOLO1/2 (Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis) trials (38%), [11] but mean changes i…”
ResultAutoreactive T cells and their role in atopic dermatitis
Carlier, T. D. B., Badloe, F. M. S., Ring, J., Gutermuth, J., & Krohn, I. K. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102634 · Cited by 43
Lobo, Y., Lee, R. C., & Spelman, L. J. (2021) · Case Reports in Dermatology · doi:10.1159/000515246 · Cited by 40
Atopic dermatitis: Is innate or adaptive immunity in control? A clinical perspective
Ong, P. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943640 · Cited by 48
“The efficacy of blocking both IL-4 and IL-13 by dupilumab, which targets the IL-4a receptor, has been shown in both phase 2 and 3 trials (7, 8).”
BackgroundThe current state of knowledge of the immune ecosystem in alopecia areata
Connell, S. J., & Jabbari, A. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103061 · Cited by 44
Atopic Dermatitis: Clinical Aspects and Unmet Needs
Lobefaro, F., Gualdi, G., Nuzzo, S. D., & Amerio, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112927 · Cited by 60
Thormann, K., Lüthi, A., Deniau, F., Heider, A., Cazzaniga, S., Radonjic‐Hoesli, S., Lehmann, M., Schlapbach, C., Herzog, E. L., Kreuzer, M., et al. (2024) · Allergy · doi:10.1111/all.16045 · Cited by 43
New and Emerging Therapies for Pediatric Atopic Dermatitis
Nguyen, H. L., Anderson, K., & Tollefson, M. M. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00342-w · Cited by 41
Endotype-driven precision medicine in chronic rhinosinusitis
Lou, H., Wang, C., & Zhang, L. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1679626 · Cited by 41
“Dupilumab is a fully human anti-IL4Rα mAb approved for the treatment of patients with moderate-to-severe atopic dermatitis and asthma [116,117].”
BackgroundCurrent and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis
Chun, P. I. F., & Lehman, H. K. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08802-9 · Cited by 41
“The studies examined two dupilumab arms vs placebo; a loading dose of 600 mg subcutaneously followed by 300 mg SQ weekly for 16 weeks, or a loading dose of 600 mg SQ followed by 300 mg SQ every other week for 16 weeks [46].”
MethodPark, K. Y., Han, H. S., Park, J. W., Kwon, H. H., Park, G., & Seo, S. J. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14153 · Cited by 39
Atopy as Immune Dysregulation: Offender Genes and Targets
Vaseghi‐Shanjani, M., Snow, A. L., Margolis, D. J., Latrous, M., Milner, J. D., Turvey, S. E., & Biggs, C. M. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.04.001 · Cited by 40
Research Techniques Made Simple: Itch Measurement in Clinical Trials
Erickson, S. P., & Kim, B. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.004 · Cited by 47
“improvement of at least 4 points in peak NRS score at weeks 2, 4, and 16 or of at least 3 points at week 16 in the weekly average of daily peak NRS scores (Simpson et al., 2016).”
BackgroundZeze, N., Kido‐Nakahara, M., Tsuji, G., Maehara, E., Sato, Y., Sakai, S., Fujishima, K., Hashimoto‐Hachiya, A., Furue, M., & Nakahara, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073467 · Cited by 42
“However, not all skin rashes disappear, even with new systemic therapy, such as dupilumab or baricitinib [14,31,32], and it is important to combine it with topical therapy.”
BackgroundTakahashi, K., Miyake, K., Ito, J., Shimamura, H., Suenaga, T., Karasuyama, H., & Ohashi, K. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.09.272 · Cited by 47
Biologics in patients with skin diseases
Veilleux, M. S., & Shear, N. H. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.012 · Cited by 39
Treatment of Atopic Dermatitis with Biologic Drugs
Fabbrocini, G., Napolitano, M., Megna, M., Balato, N., & Patruno, C. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0258-x · Cited by 43
Emerging Therapeutic Options for Chronic Pruritus
Reszke, R., Krajewski, P. K., & Szepietowski, J. C. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00534-y · Cited by 41
Sears, A. V., Woolf, R., Gribaleva, E., Abdelrahman, W., Robbie, S. J., Menon, B. S., Kirkham, B. W., Smith, C. H., & Pink, A. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19631 · Cited by 38
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis
Yang, N., Chen, Z., Zhang, X., & Shi, Y. (2021) · BioDrugs · doi:10.1007/s40259-021-00490-x · Cited by 39
Grolleau, C., Călugăreanu, A., Demouche, S., Nosbaum, A., Staumont-Sallé, D., Aubert, H., Cassius, C., Jachiet, M., Saussine, A., Bagot, M., et al. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.10.015 · Cited by 42
Napolitano, M., Fabbrocini, G., & Patruno, C. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16764 · Cited by 44
Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience
Portacci, A., Iorillo, I., Quaranta, V. N., Maselli, L., Lulaj, E., Buonamico, E., Dragonieri, S., & Carpagnano, G. E. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107348 · Cited by 41
Atopic Dermatitis Itch: Scratching for an Explanation
Soares, G. B., Hashimoto, T., & Yosipovitch, G. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.10.048 · Cited by 44
Ardern‐Jones, M. R., Brown, S., Flohr, C., Hossain, P. N., Irvine, A. D., Johnston, G. A., Lane, M., Langan, S., Laws, P., O’Driscoll, D., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae344 · Cited by 45
Nettis, E., Patella, V., Lombardo, C., Detoraki, A., Macchia, L., Leo, E. D., Carbonara, M., Canonica, G. W., & Bonzano, L. (2020) · Allergy · doi:10.1111/all.14338 · Cited by 38
Sims, J. T., Chang, C.-Y., Higgs, R. E., Engle, S., Liu, Y., Sissons, S. E., Rodgers, G. H., Simpson, E. L., Silverberg, J. I., Forman, S. B., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14389 · Cited by 39
Self-citationParker, J. J., Sugarman, J. L., Silverberg, N. B., González, M. E., Ramien, M., Teng, J. M. C., & Paller, A. S. (2021) · Pediatric Dermatology · doi:10.1111/pde.14820 · Cited by 37
Consensus Update for Systemic Treatment of Atopic Dermatitis
Lee, J. H., Kim, J. E., Park, G., Bae, J. M., Byun, J. Y., Shin, M. K., Han, T. Y., Hong, S., Jang, Y. H., Kim, H. O., et al. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.6.497 · Cited by 39
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians
Muzumdar, S., Skudalski, L., Sharp, K. L., & Waldman, R. A. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00646-z · Cited by 45
Han, H. S., Koh, Y. G., Hong, J. K., Roh, Y. J., Seo, S. J., & Park, K. Y. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2220444 · Cited by 39
An inflammation-responsive double-layer microneedle patch for recurrent atopic dermatitis therapy
Song, L., Chi, J., Li, Z., Tao, Y., Sun, Y., Zhou, Q., Lu, S., Huang, S., Huang, S., Lu, X., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123215 · Cited by 42
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
Lin, T., Fan, Y., Fan, K.-S., Juan, C., Chen, Y., & Wu, C.-Y. (2025) · JAMA Dermatology · doi:10.1001/jamadermatol.2025.1578 · Cited by 42
Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Agarwal, A., Spath, D., Sherris, D. A., Kita, H., & Ponikau, J. U. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08734-z · Cited by 37
“In March of 2017, dupilumab was approved for treatment of patients with moderate to severe atopic dermatitis whose symptoms are not controlled with topical prescription therapies [31].”
BackgroundManagement of Itch in the Elderly: A Review
Fourzali, K. M., & Yosipovitch, G. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-00326-1 · Cited by 40
“Dupilumab, a monoclonal antibody targeting the receptor for IL-4, has been shown in large RCTs to reduce symptoms and improve quality of life in those with moderate to severe AD [110, 111].”
BackgroundEarly development of the skin microbiome: therapeutic opportunities
Casterline, B. W., & Paller, A. S. (2020) · Pediatric Research · doi:10.1038/s41390-020-01146-2 · Cited by 41
Schneeweiss, M. C., Kim, S. C., Wyss, R., Schneeweiß, S., & Merola, J. F. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.084 · Cited by 38
Kumar, P., Sharma, D. K., & Ashawat, M. S. (2021) · Journal of Liposome Research · doi:10.1080/08982104.2021.1880436 · Cited by 38
Sun, Y., Dong, Y., Liu, X., Zhang, Y., Bai, H., Duan, J., Tian, Z., Xiang, Y., Wang, J., & Wang, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104200 · Cited by 39
The Communication from Immune Cells to the Fibroblasts in Keloids: Implications for Immunotherapy
Zhang, X., Wu, X., & Li, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015475 · Cited by 46
“Furthermore, dupilumab relieved pruritus in a phase 3 study of patients with moderate-to-severe AD, indicating that it plays a role in blocking signals from itch neurons [52] and may also improve pruritus of keloids.”
BackgroundDupilumab in atopic dermatitis: rationale, latest evidence and place in therapy
Ariëns, L. F. M., Bakker, D. S., van der Schaft, J., Garritsen, F. M., Thijs, J. L., & de Bruin-Weller, M. S. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318773686 · Cited by 39
“Therapeutic Advances in Chronic Disease 9(9)”
Relative efficacy of systemic treatments for atopic dermatitis
Seger, E. W., Wechter, T., Strowd, L. C., & Feldman, S. R. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.09.053 · Cited by 36
Current pharmaceutical developments in atopic dermatitis
Misery, L., Huet, F., Gouin, O., Ständer, S., & Deleuran, M. S. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.12.003 · Cited by 39
Self-citationBiologics for chronic inflammatory skin diseases: an update for the clinician
Yao, Y., Jørgensen, A. R., & Thomsen, S. F. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1589643 · Cited by 37
“In mice, over-expression of IL-4 and IL-13 induces dermal lesions, dryness, and inflammation resulting in dermal phenotypes similar to atopic dermatitis (AD) in humans (59).”
BackgroundDupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas
Lazaridou, I., Ram‐Wolff, C., Bouaziz, J., Bégon, E., Battistella, M., Rivet, J., Jachiet, M., Bagot, M., & de Masson, A. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3576 · Cited by 35
“In AD, dupilumab treatment significantly improves pruritus (2).”
BackgroundAdvances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch
Kahremany, S., Hofmann, L., Gruzman, A., & Cohen, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144883 · Cited by 37
Topical therapy of atopic dermatitis with a focus on pimecrolimus
Luger, T. A., Paller, A. S., Irvine, A. D., Sidbury, R., Eichenfield, L. F., Werfel, T., & Bieber, T. R. M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17272 · Cited by 43
Self-citationShen, C., Liu, C., Zhang, Z., Yü, P., Shao, J., Tian, Y., Yu, W., Qin, G., Liu, S., Wang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680055 · Cited by 40
Dupilumab-induced psoriasis and alopecia areata: Case report and review of the literature
Beaziz, J., Bouaziz, J., Jachiet, M., Fite, C., & Lons‐Danic, D. (2021) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2021.02.003 · Cited by 35
Documento de consenso de asma grave en adultos. Actualización 2022
Gutiérrez, F. J. Á., Blanco‐Aparicio, M., Maldonado, F. C., Plaza, V., González‐Barcala, F. J., Carretero-Gracia, J. Á., Castilla-Martínez, M., Cisneros, C., Díaz-Pérez, D., Domingo, C., et al. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100192 · Cited by 75
The spectrum of allergic ocular diseases
Rodrigues, J., Kuruvilla, M. E., Vanijcharoenkarn, K., Patel, N., Hom, M. M., & Wallace, D. V. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.11.016 · Cited by 38
Yang, S. K., Cho, S., & Kim, D. W. (2022) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2022.14.5.465 · Cited by 35
S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment
Werfel, T., Heratizadeh, A., Aberer, W., Augustin, M., Biedermann, T., Bauer, A., Fölster‐Holst, R., Kahle, J., Kinberger, M., Nemat, K., et al. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15229 · Cited by 52
“13 Dupilumab showed significant clinical effects in the evaluation of severity assessed by means of Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), and SCORing Atopic Dermatitis (SCO-RAD).”
MethodSelf-citationMcDonald, V. M., Hamada, Y., Agustí, A. G. N., & Gibson, P. G. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.01.020 · Cited by 35
Lieberman, P., Chu, D. K., Ahmed, T., Dribin, T. E., Abrams, E. M., Anagnostou, A., Blumenthal, K. G., Boguniewicz, M., Chase, N. M., Golden, D. B. K., et al. (2024) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2024.05.014 · Cited by 37
Leyva-Castillo, J. M., Das, M., Strakosha, M., McGurk, A. I., Artru, E., Kam, C., Alasharee, M., Wesemann, D. R., Tomura, M., Karasuyama, H., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.06.021 · Cited by 37
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review
Torres, T. R., Mendes‐Bastos, P., Cruz, M. J., Duarte, B., Filipe, P., Lopes, M. J. P., & Gonçalo, M. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01352-y · Cited by 46
“These benefits have been sustained over time, even in real‑world settings, with a favorable safety profile [87–89].”
Staphylococcus aureus in Inflammation and Pain: Update on Pathologic Mechanisms
Rasquel-Oliveira, F. S., Ribeiro, J. M., Martelossi-Cebinelli, G., Costa, F., Nakazato, G., Casagrande, R., & Verri, W. A., Jr. (2025) · Pathogens · doi:10.3390/pathogens14020185 · Cited by 51
Long‐term off‐label dupilumab in pediatric atopic dermatitis: A case series
Treister, A. D., & Lio, P. (2018) · Pediatric Dermatology · doi:10.1111/pde.13697 · Cited by 34
“Clinical trials of dupilumab have shown efficacy in adult patients with moderate‐to‐severe AD with a significantly greater percent of treated patients achieving clear or almost clear skin as compared to placebo.(3,4) This medication has generally been well tolerated with less concern for toxicity as compared to other…”
ResultYamane, M. L. M., Belsito, D. V., & Glass, L. R. D. (2019) · Orbit · doi:10.1080/01676830.2018.1553190 · Cited by 34
Bateman, E. D., Khan, A. H., Xu, Y., Guyot, P., Chao, J., Kamat, S., Rowe, P., Burnett, H. F., Msihid, J., Weinreich, D. M., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105991 · Cited by 39
Innovation in Atopic Dermatitis: From Pathogenesis to Treatment
Munera‐Campos, M., & Carrascosa, J. M. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2020.03.001 · Cited by 34
“Dupilumab was also superior for all secondary outcome measures (EASI-75, reduction of pruritus, symptoms of anxiety and depression, quality of life, and need for rescue medication) compared with placebo.(12,13) Another phase III RCT has also reported positive findings for dupilumab in combination with topical corticos…”
Kwatra, S. G., Gruben, D. C., Fung, S., & DiBonaventura, M. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01630-z · Cited by 40
“improving the signs and symptoms of the disease [26].”
BackgroundThe Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis
Wong, L., Yen, Y.-T., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137227 · Cited by 36
“Dupilumab, a humanized IL-4 receptor α blocker, has been approved for the treatment of AD and has shown a significant and rapid reduction in both pruritus and severity of AD [93,94].”
Background
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.